CG Oncology
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s prod...
Latest News
14 hours ago · benzinga.com
CG Oncology Celebrates Defining Milestone As Bladder Cancer Trial SucceedsCG Oncology Inc. (NASDAQ:CGON) on Monday announced positive topline results from its Phase 3 PIVOT-006 trial, which Arthur Kuan, chairman, president, and CEO of CG Oncology, called a defining milestone for the company.
14 hours ago · schaeffersresearch.com
2 Cancer-Drug Developers Seeing Unusual Options VolumeTwo cancer drug developers are seeing unusual options activity today, with Summit Therapeutics Inc (NASDAQ:SMMT) and CG Oncology Inc (NASDAQ:CGON) moving in opposite directions following major clinical and regulatory developments.
16 hours ago · investors.com
CG Oncology Exceeds Even The 'Most Bullish Conversations;' Shares Break OutCG Oncology said Monday its experimental bladder cancer treatment cut the risk of recurrence by 68%. The biotech stock broke out.
19 hours ago · globenewswire.com
PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)– Cretostimogene reduced the risk of recurrence by 68%, demonstrating a statistically significant and clinically meaningful benefit with a hazard ratio of 0.32 (95% CI: 0.23, 0.45; p
11 days ago · zacks.com
CG Oncology, Inc. (CGON) Reports Q3 Loss, Beats Revenue EstimatesCG Oncology, Inc. (CGON) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $0.57 per share a year ago.
11 days ago · globenewswire.com
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business UpdatesDALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the third quarter ended September 30, 2026, and provided business updates.
21 days ago · seekingalpha.com
CG Oncology: A Second-Mover Advantage In Bladder-Sparing TherapyCG Oncology is well-positioned to enter a de-risked NMIBC market with cretostimogene, offering a clean tolerability profile and randomized Phase 3 data. CGON's $1B+ cash position funds operations through 2029, with recent ATM activity signaling strong institutional interest rather than funding desperation. PIVOT-006 trial and BLA completion are imminent catalysts; positive results could unlock significant intermediate-risk NMIBC market potential.
1 month ago · globenewswire.com
CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial OfficerDALLAS, Oct. 13, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. A highly accomplished biopharmaceutical executive with more than 20 years of commercial leadership experience, Ms.
1 month ago · gurufocus.com
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law FirmKuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law FirmPR NewswireNEW YORK, Oct. 12, 2026NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC
2 months ago · seekingalpha.com
CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptCG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove CGON